Resverlogix stock analysis
Resverlogix (0VF9) Share Price & Analysis
0VF9 Stock Chart & Stats
- Day’s Range
- CAD 0.09 - CAD 0.10
- 52-Week Range
- CAD 0.09 - CAD 0.12
- Previous Close
- CAD 0.10
- Volume
- N/A
- Average Volume (3M)
- 0
- Market Cap
- CAD 25.82M
- Enterprise Value
- CAD 141.04M
- Total Cash (Recent Filing)
- CAD 156.99K
- Total Debt (Recent Filing)
- CAD 77.18M
- Price to Earnings (P/E)
- ―
- Beta
- 1.30
- Next Earnings
- Apr 05, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Focused Epigenetic Drug Platform
A defined focus on small-molecule epigenetic therapies gives Resverlogix a coherent development strategy and concentrates resources around related cardiovascular and metabolic applications. This specialization could support cumulative scientific and intellectual-property value as programs advance.
Cash Flow Tracks Reported Losses
Free cash flow closely tracking net loss indicates that reported losses are largely reflected in actual cash consumption rather than being driven primarily by large non-cash charges. That alignment improves the transparency of financial performance and cash needs.
Recent Free Cash Flow Improvement
The reported improvement in free cash flow versus 2025 suggests some progress in moderating cash consumption, even though the company remains cash-burning. If sustained, better cash-flow performance could modestly extend funding capacity and reduce pressure on future financing.
Bears Say
No Revenue And Worsening Losses
ไม่มี revenue leaves Resverlogix without operating income to fund research, while the larger TTM loss shows profitability has deteriorated. Continued negative EBIT and EBITDA limit operating leverage and make progress dependent on successful development or external financing.
Severely Leveraged Balance Sheet
Deeply negative equity and debt that greatly exceeds the asset base indicate a very thin financial cushion. This structure heightens refinancing and solvency risk, reduces flexibility to absorb setbacks, and can constrain investment in clinical development or commercialization.
Persistent Cash Funding Requirement
Negative operating and free cash flow show that the business currently consumes cash rather than funding itself. Persistent burn increases dependence on financing, while the fragile balance sheet may make raising or refinancing capital more difficult over the next several quarters.
Resverlogix News
0VF9 FAQ
What was Resverlogix’s price range in the past 12 months?
What is Resverlogix’s market cap?
When is Resverlogix’s upcoming earnings report date?
How were Resverlogix’s earnings last quarter?
Is Resverlogix overvalued?
Does Resverlogix pay dividends?
What is Resverlogix’s EPS estimate?
How many shares outstanding does Resverlogix have?
What happened to Resverlogix’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Resverlogix?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Resverlogix
Resverlogix Corporation is a biotechnology firm currently in advanced clinical development, concentrating on developing treatments for illnesses where existing medical solutions are inadequate. The company's leading therapeutic compound is apabetalone (RVX-208), a selective small molecule designed to inhibit bromodomain and extra-terminal proteins. This compound is presently undergoing pivotal Phase III clinical trials for patients afflicted with conditions such as cardiovascular disease, diabetes, various stages of kidney disease (including end-stage renal disease), and neurodegenerative disorders. Furthermore, Resverlogix Corp. has forged an alliance with Eversana Life Science Services, LLC to support the forthcoming commercial rollout of apabetalone as a treatment for COVID-19 across the United States and Canada. The company's main office is located in Calgary, Canada.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Donald J. McCaffrey
- Employees
- 17
- Website
- www.resverlogix.com
- Address
- 4820 Richard Road SW, Calgary, AB, T3E 6L1, CA
Resverlogix (0VF9) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 4 | 1 | 13 |
| Technical Analysis | 2 | 0 | 4 |
| Moving Averages | 2 | 1 | 9 |









